We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dropping from a high of 47 requests for Regenerative Medicine Advanced Therapy (RMAT) designations in 2018, the FDA has received, so far, just 14 requests this year, according to new data from the FDA’s Center for Biologics Evaluation and Research (CBER). Read More
Claims by CofixRX for its iodine-containing nasal spray render it an unapproved new drug that is misbranded and adulterated, the FDA said, in a warning letter to the company in Rochester Hills, Mich. Read More
Last week’s Aduhelm coverage decision by the Centers for Medicare and Medicaid Services (CMS) raises the bar for three other antiamyloid antibodies in late-stage development: Eisai’s and Biogen’s lecanemab, Eli Lilly’s donanemab and Roche’s gantenerumab. It all depends on the evidence that the drugmakers provide in their submissions to the FDA. Read More
The FDA and Centers or Medicare and Medicaid Services (CMS) took the rare step Friday of issuing a joint statement to clarify their regulatory authorities one day after the CMS made a controversial decision on who will have Medicare-paid access to the Alzheimer’s drug Aduhelm (aducanumab). Read More
The FDA is proposing a rating system to assess drugmakers’ quality management maturity (QMM) as a way to protect against drug shortages and bolster the U.S. supply chain. Read More
The FDA has released final guidance marking the agency’s adoption of the International Council for Harmonization (ICH)’s E8(R1) guidelines on clinical trials, which call for a “quality by design” approach. Read More
Sensory Cloud of Boston, Mass., has received a warning letter from the FDA for promoting an unapproved saline spray device as a COVID-19 treatment. Read More
The FDA is reaching out to states that have filed applications with the agency seeking approval to directly import prescription medicines from Canada. Read More
Alzheimer’s disease drug Aduhelm and other investigational anti-amyloid antibodies similar to Aduhelm will only be covered by Medicare and Medicaid if they’re used in the setting of a federally approved study, the Centers for Medicare and Medicaid Services (CMS) announced yesterday. Read More